
    
      This pilot study is focused on maintenance Zydelig for patients with indolent or transformed
      indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL) after autologous stem cell
      transplantation. Oral Zydelig at 150 mg (or adjusted dose) twice daily continuously on 28-day
      cycles. Patients will continue on Zydelig up to one year or to progression/relapse/death or
      unacceptable toxicity, whichever occurs first.
    
  